Pacific Biosciences of California Inc. (PACB)

7.66
0.01 0.13
NASDAQ : Health Technology
Prev Close 7.65
Open 7.69
Day Low/High 7.65 / 7.71
52 Wk Low/High 2.02 / 7.84
Volume 3.42M
Avg Volume 3.30M
Exchange NASDAQ
Shares Outstanding 148.90M
Market Cap 1.15B
EPS -0.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Illumina To Acquire Pacific Biosciences For Approximately $1.2 Billion, Broadening Access To Long-Read Sequencing And Accelerating Scientific Discovery

Illumina To Acquire Pacific Biosciences For Approximately $1.2 Billion, Broadening Access To Long-Read Sequencing And Accelerating Scientific Discovery

Illumina, Inc. (NASDAQ: ILMN) and Pacific Biosciences (NASDAQ:PACB) today announced they have signed an agreement for Illumina to acquire Pacific Biosciences at a price of $8.

First Week Of June 2019 Options Trading For Pacific Biosciences Of California (PACB)

First Week Of June 2019 Options Trading For Pacific Biosciences Of California (PACB)

Investors in Pacific Biosciences of California Inc saw new options begin trading this week, for the June 2019 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 239 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Interesting PACB Put Options For November 16th

Interesting PACB Put Options For November 16th

Investors in Pacific Biosciences of California Inc saw new options begin trading this week, for the November 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PACB options chain for the new November 16th contracts and identified the following put contract of particular interest.

Pacific Biosciences Of California Reaches Analyst Target Price

Pacific Biosciences Of California Reaches Analyst Target Price

In recent trading, shares of Pacific Biosciences of California Inc have crossed above the average analyst 12-month target price of $4.33, changing hands for $4.36/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

PACB Crosses Above Average Analyst Target

PACB Crosses Above Average Analyst Target

In recent trading, shares of Pacific Biosciences of California Inc have crossed above the average analyst 12-month target price of $3.92, changing hands for $4.09/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Study Demonstrates Potential For SMRT Sequencing To Improve The Safety Of Gene Therapy Protocols

Study Demonstrates Potential For SMRT Sequencing To Improve The Safety Of Gene Therapy Protocols

Clinical Research Effort Establishes New Quality Control Standards and Reveals Previously Undetected Risks for Gene Therapy Delivery

Pacific Biosciences Enhances Performance And Affordability Of Key Applications On The Sequel System

Pacific Biosciences Enhances Performance And Affordability Of Key Applications On The Sequel System

New Polymerase and Software Releases Improve Structural Variant Detection, Targeted Sequencing and RNA Sequencing Applications

SMRT Sequencing Of Human Genomes To Be Showcased At AGBT Conference

SMRT Sequencing Of Human Genomes To Be Showcased At AGBT Conference

Presentations will highlight importance of SMRT Sequencing for rare diseases, structural variation, and more

Pacific Biosciences Announces Fourth Quarter And Annual 2017 Financial Results

Pacific Biosciences Announces Fourth Quarter And Annual 2017 Financial Results

Annual Product and Service Revenue Increases 19% Year over Year

Commit To Purchase Pacific Biosciences of California At $2.50, Earn 24.4% Annualized Using Options

Commit To Purchase Pacific Biosciences of California At $2.50, Earn 24.4% Annualized Using Options

Investors eyeing a purchase of Pacific Biosciences of California Inc stock, but cautious about paying the going market price of $3.21/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the September put at the $2.50 strike, which has a bid at the time of this writing of 40 cents.

Pacific Biosciences Shares Down After Third-Quarter Results -- Biotech Movers

Pacific Biosciences Shares Down After Third-Quarter Results -- Biotech Movers

The Menlo Park, Calif.-based firm had a third-quarter net loss of $22 million, compared with $17.5 million in the year-ago period. Product, service and other revenue rose 9% year-over-year to $23.5 million.

Pacific Biosciences Of California, Inc. Announces Third Quarter 2017 Financial Results

Pacific Biosciences Of California, Inc. Announces Third Quarter 2017 Financial Results

Product and Service Revenue Increases by 9% Over Same Period in Previous Year

Pacific Biosciences of California Becomes Oversold (PACB)

Pacific Biosciences of California Becomes Oversold (PACB)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Recent Projects Highlight Success Of SMRT Sequencing For Characterizing Structural Variation In Human Genomes

Recent Projects Highlight Success Of SMRT Sequencing For Characterizing Structural Variation In Human Genomes

PacBio Sequencing Reveals More Functionally Important Variants; Complete Solution for Structural Variant Detection to be Featured at ASHG Annual Meeting

Structural Variation Detection A Key Focus Of PacBio Sequencing Projects Presented At ASHG Annual Meeting

Structural Variation Detection A Key Focus Of PacBio Sequencing Projects Presented At ASHG Annual Meeting

More than 30 presentations demonstrate utility of SMRT Sequencing for human biomedical applications

Commit To Buy Pacific Biosciences of California At $5, Earn 34.4% Annualized Using Options

Commit To Buy Pacific Biosciences of California At $5, Earn 34.4% Annualized Using Options

Investors considering a purchase of Pacific Biosciences of California Inc shares, but cautious about paying the going market price of $5.10/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the March 2018 put at the $5 strike, which has a bid at the time of this writing of 90 cents.

Pacific Biosciences Of California, Inc. Announces Second Quarter 2017 Financial Results

Pacific Biosciences Of California, Inc. Announces Second Quarter 2017 Financial Results

Product and Service Revenue Increases by 17% Over Same Period in Previous Year

TheStreet Quant Rating: D- (Sell)